Fermenta Biotech Past Earnings Performance
Past criteria checks 0/6
Fermenta Biotech's earnings have been declining at an average annual rate of -65.4%, while the Pharmaceuticals industry saw earnings growing at 14.2% annually. Revenues have been declining at an average rate of 1.4% per year.
Key information
-65.4%
Earnings growth rate
-65.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | -1.4% |
| Return on equity | -8.0% |
| Net Margin | -6.0% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Fermenta Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 3,435 | -207 | 600 | 0 |
| 30 Sep 23 | 2,994 | -670 | 601 | 0 |
| 30 Jun 23 | 3,405 | -471 | 569 | 0 |
| 31 Mar 23 | 3,499 | -515 | 618 | 0 |
| 31 Dec 22 | 3,422 | -401 | 661 | 0 |
| 30 Sep 22 | 3,814 | -107 | 661 | 0 |
| 30 Jun 22 | 3,808 | 15 | 646 | 0 |
| 31 Mar 22 | 3,985 | 154 | 661 | 0 |
| 31 Dec 21 | 4,018 | 152 | 615 | 0 |
| 30 Sep 21 | 3,990 | 330 | 597 | 0 |
| 30 Jun 21 | 3,925 | 432 | 587 | 0 |
| 31 Mar 21 | 3,773 | 455 | 606 | 0 |
| 31 Dec 20 | 3,423 | 412 | 622 | 0 |
| 30 Sep 20 | 3,188 | 411 | 592 | 0 |
| 30 Jun 20 | 3,062 | 591 | 623 | 0 |
| 31 Mar 20 | 2,929 | 595 | 590 | 0 |
| 31 Dec 19 | 3,200 | 877 | 464 | 0 |
| 30 Sep 19 | 3,652 | 1,060 | 545 | 0 |
| 30 Jun 19 | 4,057 | 1,081 | 587 | 0 |
| 31 Mar 19 | 4,047 | 1,175 | 573 | 0 |
| 31 Dec 18 | 4,100 | 904 | 568 | 0 |
| 30 Sep 18 | 3,966 | 834 | 542 | 0 |
| 30 Jun 18 | 3,391 | 550 | 724 | 0 |
| 31 Mar 18 | 3,027 | 337 | 433 | 0 |
| 31 Dec 17 | 2,521 | 380 | 537 | 0 |
| 30 Sep 17 | 1,914 | 146 | 424 | 0 |
| 30 Jun 17 | 1,678 | 53 | 346 | 0 |
| 31 Mar 17 | 1,641 | -114 | 334 | 0 |
| 31 Dec 16 | 1,567 | 107 | 333 | 0 |
| 30 Sep 16 | 1,552 | 168 | 325 | 0 |
| 30 Jun 16 | 1,541 | -24 | 327 | 0 |
| 31 Mar 16 | 1,548 | -11 | 305 | 0 |
| 31 Dec 15 | 1,506 | 41 | 410 | 0 |
| 30 Sep 15 | 1,428 | 12 | 398 | 0 |
| 30 Jun 15 | 1,422 | 9 | 278 | 0 |
| 31 Mar 15 | 1,319 | 5 | 260 | 0 |
| 31 Dec 14 | 1,262 | 17 | 364 | 0 |
| 30 Sep 14 | 1,455 | 78 | 366 | 0 |
| 30 Jun 14 | 1,500 | 78 | 263 | 0 |
| 31 Mar 14 | 1,392 | 79 | 344 | 0 |
| 31 Dec 13 | 1,186 | 38 | 337 | 0 |
| 30 Sep 13 | 1,016 | 8 | 325 | 0 |
| 30 Jun 13 | 1,125 | 18 | 237 | 0 |
Quality Earnings: 506414 is currently unprofitable.
Growing Profit Margin: 506414 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 506414 is unprofitable, and losses have increased over the past 5 years at a rate of 65.4% per year.
Accelerating Growth: Unable to compare 506414's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 506414 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (23.1%).
Return on Equity
High ROE: 506414 has a negative Return on Equity (-7.98%), as it is currently unprofitable.